Streetbeat News

Regulatory

BLUE

Concerns are rising over Bluebird Bio's gene therapy as new data shows an increase in cancer cases among treated children. Seven out of 67 children developed blood cancers, up from three cases in June 2022. The FDA had previously approved the therapy, Skysona, despite these concerns. Bluebird Bio has also faced workforce reductions and financial challenges.

Portfolio Pulse from Vandana Singh

October 11, 2024 | 1:09 pm

CNEY

CNEY has regained compliance with Nasdaq's listing requirements, which is a positive development for the company and its investors.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 1:03 pm

CLOV

Clover Health's shares are rising following an upgrade in the Star rating of its PPO Medicare Advantage plans to 4 Stars for 2025 by the Centers for Medicare and Medicaid Services.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 12:56 pm

ALCE

Trading for ALCE was halted and has now resumed as of 8:55:00 AM ET. The halt was due to pending news, and trading has now resumed following the release of this information.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 12:55 pm

JPM

JP Morgan's CFO highlighted ongoing uncertainties in the M&A regulatory environment and geopolitical situation during a media call.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 12:38 pm

CATX

Perspective Therapeutics is advancing the development of its radiopharmaceutical therapy [212Pb]VMT01 following promising data presented at the Society for Melanoma Research Congress. The therapy showed safety and efficacy in heavily pretreated patients, with no dose-limiting toxicities and prolonged progression-free survival. The trial is now testing a lower dose to optimize treatment in melanoma, both as a monotherapy and in combination with Nivolumab.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 12:32 pm

ABTS

Abits Group Inc (NASDAQ:ABTS) has received a 180-day extension from NASDAQ to comply with the minimum bid price requirement, needing its share price to be at least $1.00 for ten consecutive days by April 7, 2025.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 12:31 pm

SPY

The Core Producer Price Index (PPI) for September increased by 2.8% year-over-year, surpassing the expected 2.7% and the previous 2.4%. This indicates higher-than-anticipated inflationary pressures.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 12:30 pm

TSLA

Tesla's stock is experiencing a pullback due to investor disappointment following the 'We, Robot' event. The unveiling of the Cybercab, an autonomous vehicle, did not meet market expectations, and its production timeline is set for 2026 or later, causing concern among investors.

Portfolio Pulse from Shanthi Rexaline

October 11, 2024 | 12:10 pm

NA

Nano Labs has regained compliance with Nasdaq's minimum market value of publicly held shares requirement, ensuring its continued listing on the exchange.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 12:08 pm